Keyword: Array BioPharma

Pfizer sign

5. Pfizer/Array BioPharma

Buying oncology specialist Array BioPharma is Pfizer CEO Albert Bourla’s biggest M&A move so far. It represents another big bet by the New York drugmaker on cancer treatments since its $14.3 billion deal for Medivation.
People shaking hands across a desk that has computer and papers on it

The top 10 largest biopharma M&A deals in 2019

Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity.